Clinica's Medtech Ventures: Issue 4: Vivoxid to tackle worldwide orthopaedic market with bioactive glass
This article was originally published in Clinica
Company: Vivoxid Specialty area(s): Biomaterials Based in: Turku, Finland Founded in: 2001 No. of employees: 25 Total investment received to date: E7m ($9.6m) from Sitra, Varma Mutual Pension Insurance Company, Sentica Partners
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.